30Jan 2024
Argatroban in Patients With Acute Ischemic Stroke With Early Neurological Deterioration

Argatroban in Patients With Acute Ischemic Stroke With Early Neurological Deterioration

A randomized clinical trial involving 628 patients with acute ischemic stroke (AIS) and early neurological deterioration (END) assessed the efficacy of argatroban. In the argatroban group (n=314), 80.5% had a good functional outcome at 90 days, compared to 73.3% in the control group (n=314). The risk difference was 7.2%, with a risk ratio of 1.10. The proportion of symptomatic intracranial hemorrhage was similar between groups. The study suggests that argatroban, combined with antiplatelet therapy, improves functional outcomes in AIS patients with END, supporting its use in reducing disability.

  • #neurology

Like

Save

Share